Outlook Therapeutics Q1 Net Loss Narrows to $13.5M Adjusted as LYTENAVA Sales Double
Outlook Therapeutics posted a Q1 net loss of $23.1 million ($0.38/share) compared with a $17.4 million profit, and narrowed adjusted net loss to $13.5 million ($0.22/share) from $21.6 million. European LYTENAVA unit sales more than doubled after its Austria launch, with Ireland and Netherlands launches set for 2026.
1. Q1 Financial Results
Outlook Therapeutics reported a net loss of $23.1 million ($0.38/share) in the fiscal first quarter ended December 31, 2025, versus a $17.4 million net profit a year earlier. Adjusted net loss narrowed to $13.5 million ($0.22/share), excluding $6.7 million of promissory note fair value losses and $2.8 million of warrant liability adjustments.
2. European Expansion of LYTENAVA
Following its January 2026 launch in Austria, unit sales of LYTENAVA more than doubled quarter-over-quarter in Europe. Outlook Therapeutics plans to introduce the product in Ireland and the Netherlands in 2026, with France, Italy and Spain targeted in 2027, and is exploring partnerships in Latin America and Asia.
3. Adjusted Net Loss and Cash Position
Revenue was affected by an increased returns reserve for short-dated product from the UK distributor, with no further adjustments expected for fiscal 2026. As of December 31, 2025, the company held $8.7 million in cash and cash equivalents, plus $2.4 million of net proceeds from its at-the-market offering program received after quarter end.
4. FDA Regulatory Update for ONS-5010
Outlook Therapeutics submitted a Type A meeting request to the FDA to address a Complete Response Letter for its ONS-5010 biologics license application, citing a single deficiency on efficacy evidence. The company argues that data from the NORSE TWO study and other confirmatory evidence support approval and seeks FDA guidance on additional requirements.